Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing.
El-Saghir
Nagi
N
Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. nagi.saghir@aub.edu.lb
Otrock
Zaher
Z
Mufarrij
Afif
A
Abou-Mourad
Yasser
Y
Salem
Ziad
Z
Shamseddine
Ali
A
Abbas
Jaber
J
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D015552:Injections, Intralesional; D016032:Randomized Controlled Trials as Topic; D011929:Razoxane / Q000008:administration & dosage / Q000627:therapeutic use*; D012883:Skin Ulcer / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D013909:Thorax; D014945:Wound Healing
D002614:Chelating Agents; D011929:Razoxane; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor